These findings indicate that identifying tumour-derived osteoclastogenic factors, such as VCAM-1 and PTHrP, might provide new potential therapeutic targets for preventing and inhibiting metastatic recurrence in bone. This evidence concerns the gene PTHLH and neoplasm.